EA200501677A2 - PHOSPHONETIC CONTAINING CONNECTIONS (OPTIONS), PHARMACEUTICAL COMPOSITION (OPTIONS) AND DRUG FORM ON THEIR BASIS, METHOD OF TREATING CANCER (OPTIONS) AND METHOD OF PRESENTING THE CANCER OF OPERATORS - Google Patents

PHOSPHONETIC CONTAINING CONNECTIONS (OPTIONS), PHARMACEUTICAL COMPOSITION (OPTIONS) AND DRUG FORM ON THEIR BASIS, METHOD OF TREATING CANCER (OPTIONS) AND METHOD OF PRESENTING THE CANCER OF OPERATORS

Info

Publication number
EA200501677A2
EA200501677A2 EA200501677A EA200501677A EA200501677A2 EA 200501677 A2 EA200501677 A2 EA 200501677A2 EA 200501677 A EA200501677 A EA 200501677A EA 200501677 A EA200501677 A EA 200501677A EA 200501677 A2 EA200501677 A2 EA 200501677A2
Authority
EA
Eurasian Patent Office
Prior art keywords
options
cancer
phosphonetic
operators
presenting
Prior art date
Application number
EA200501677A
Other languages
Russian (ru)
Inventor
Константин Г. Буджамра
Карина Э. Канниццаро
Чанг Ю. Ким
Торстен А. Киршберг
Стивен Кравчук
Кристофер П. Ли
Куэй-Ин Линь
Давид Ю. Маркевич
Ричард Л. Мэкмэн
Петер Х. Нельсон
Дэвид Ор
Видя К. Прасад
Хюн-Цзюн Пянь
Эйдриен С. Рэй
Сандарамурти Сваминатхан
Уилл Уоткинс
Мерайя Фардис
Алан С. Хуан
Джеймс М. Чен
Сяову Чен
Дженифер Р. Чжан
Лицзюнь Чжан
Ли С. Чонг
Эзоп Чоу
Original Assignee
Джилид Сайэнс, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Джилид Сайэнс, Инк. filed Critical Джилид Сайэнс, Инк.
Priority claimed from PCT/US2004/013121 external-priority patent/WO2004096235A2/en
Publication of EA200501677A2 publication Critical patent/EA200501677A2/en

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Настоящее изобретение относится к фосфорзамещенным противораковым соединениям, к композициям, содержащим такие соединения, и к терапевтическим способам, включающим введение таких соединений, а также к способам и промежуточным производным, использованным для получения таких соединений.The present invention relates to phosphorus-substituted anticancer compounds, to compositions containing such compounds, and to therapeutic methods including the administration of such compounds, as well as to the methods and intermediate derivatives used to prepare such compounds.

EA200501677A 2003-04-25 2004-04-26 PHOSPHONETIC CONTAINING CONNECTIONS (OPTIONS), PHARMACEUTICAL COMPOSITION (OPTIONS) AND DRUG FORM ON THEIR BASIS, METHOD OF TREATING CANCER (OPTIONS) AND METHOD OF PRESENTING THE CANCER OF OPERATORS EA200501677A2 (en)

Applications Claiming Priority (124)

Application Number Priority Date Filing Date Title
US46546703P 2003-04-25 2003-04-25
US46558603P 2003-04-25 2003-04-25
US46584403P 2003-04-25 2003-04-25
US46554503P 2003-04-25 2003-04-25
US46532503P 2003-04-25 2003-04-25
US46534303P 2003-04-25 2003-04-25
US46556703P 2003-04-25 2003-04-25
US46537703P 2003-04-25 2003-04-25
US46560703P 2003-04-25 2003-04-25
US46557503P 2003-04-25 2003-04-25
US46558803P 2003-04-25 2003-04-25
US46546503P 2003-04-25 2003-04-25
US46571403P 2003-04-25 2003-04-25
US46547103P 2003-04-25 2003-04-25
US46563103P 2003-04-25 2003-04-25
US46541503P 2003-04-25 2003-04-25
US46560303P 2003-04-25 2003-04-25
US46539403P 2003-04-25 2003-04-25
US46558903P 2003-04-25 2003-04-25
US46564103P 2003-04-25 2003-04-25
US46528703P 2003-04-25 2003-04-25
US46553103P 2003-04-25 2003-04-25
US46533903P 2003-04-25 2003-04-25
US46556903P 2003-04-25 2003-04-25
US46559403P 2003-04-25 2003-04-25
US46555903P 2003-04-25 2003-04-25
US46561403P 2003-04-25 2003-04-25
US46566803P 2003-04-25 2003-04-25
US49330303P 2003-08-07 2003-08-07
US49331003P 2003-08-07 2003-08-07
US49542603P 2003-08-15 2003-08-15
US49542503P 2003-08-15 2003-08-15
US49568503P 2003-08-15 2003-08-15
US49576903P 2003-08-15 2003-08-15
US49566903P 2003-08-15 2003-08-15
US49529703P 2003-08-15 2003-08-15
US49568603P 2003-08-15 2003-08-15
US49541603P 2003-08-15 2003-08-15
US49556503P 2003-08-15 2003-08-15
US49538703P 2003-08-15 2003-08-15
US49552403P 2003-08-15 2003-08-15
US49562903P 2003-08-15 2003-08-15
US49538203P 2003-08-15 2003-08-15
US49552703P 2003-08-15 2003-08-15
US49578903P 2003-08-15 2003-08-15
US49573603P 2003-08-15 2003-08-15
US49533903P 2003-08-15 2003-08-15
US49568203P 2003-08-15 2003-08-15
US49564503P 2003-08-15 2003-08-15
US49539303P 2003-08-15 2003-08-15
US49575103P 2003-08-15 2003-08-15
US49536203P 2003-08-15 2003-08-15
US49553403P 2003-08-15 2003-08-15
US49548403P 2003-08-15 2003-08-15
US49564403P 2003-08-15 2003-08-15
US49578403P 2003-08-15 2003-08-15
US49564703P 2003-08-15 2003-08-15
US49552503P 2003-08-15 2003-08-15
US51394903P 2003-10-24 2003-10-24
US51432503P 2003-10-24 2003-10-24
US51408403P 2003-10-24 2003-10-24
US51411203P 2003-10-24 2003-10-24
US51429803P 2003-10-24 2003-10-24
US51436903P 2003-10-24 2003-10-24
US51443903P 2003-10-24 2003-10-24
US51425803P 2003-10-24 2003-10-24
US51392303P 2003-10-24 2003-10-24
US51397203P 2003-10-24 2003-10-24
US51394803P 2003-10-24 2003-10-24
US51408303P 2003-10-24 2003-10-24
US51396803P 2003-10-24 2003-10-24
US51446203P 2003-10-24 2003-10-24
US51392603P 2003-10-24 2003-10-24
US51442403P 2003-10-24 2003-10-24
US51397103P 2003-10-24 2003-10-24
US51430403P 2003-10-24 2003-10-24
US51411503P 2003-10-24 2003-10-24
US51395603P 2003-10-24 2003-10-24
US51411303P 2003-10-24 2003-10-24
US51356203P 2003-10-24 2003-10-24
US51416103P 2003-10-24 2003-10-24
US51435903P 2003-10-24 2003-10-24
US51356403P 2003-10-24 2003-10-24
US51411403P 2003-10-24 2003-10-24
US51394403P 2003-10-24 2003-10-24
US51392703P 2003-10-24 2003-10-24
US51436803P 2003-10-24 2003-10-24
US51428003P 2003-10-24 2003-10-24
US51448103P 2003-10-24 2003-10-24
US51423503P 2003-10-24 2003-10-24
US51397403P 2003-10-24 2003-10-24
US51420703P 2003-10-24 2003-10-24
US51410503P 2003-10-24 2003-10-24
US51439303P 2003-10-24 2003-10-24
US51439403P 2003-10-24 2003-10-24
US51446103P 2003-10-24 2003-10-24
US51413103P 2003-10-24 2003-10-24
US51392503P 2003-10-24 2003-10-24
US51445203P 2003-10-24 2003-10-24
US51397903P 2003-10-24 2003-10-24
US51414503P 2003-10-24 2003-10-24
US51414403P 2003-10-24 2003-10-24
US51398003P 2003-10-24 2003-10-24
US51434603P 2003-10-24 2003-10-24
US51410803P 2003-10-24 2003-10-24
US51393203P 2003-10-24 2003-10-24
US51396303P 2003-10-24 2003-10-24
US51434503P 2003-10-24 2003-10-24
US51433003P 2003-10-24 2003-10-24
US51420203P 2003-10-24 2003-10-24
US51358803P 2003-10-24 2003-10-24
US51415903P 2003-10-24 2003-10-24
US51396903P 2003-10-24 2003-10-24
US51424703P 2003-10-24 2003-10-24
US51947603P 2003-11-12 2003-11-12
US53194003P 2003-12-22 2003-12-22
US53223003P 2003-12-22 2003-12-22
US53216003P 2003-12-22 2003-12-22
US53259103P 2003-12-23 2003-12-23
US53605404P 2004-01-12 2004-01-12
US53600504P 2004-01-12 2004-01-12
US53600604P 2004-01-12 2004-01-12
US53600704P 2004-01-12 2004-01-12
PCT/US2004/013121 WO2004096235A2 (en) 2003-04-25 2004-04-26 Anti-cancer phosphonate analogs

Publications (1)

Publication Number Publication Date
EA200501677A2 true EA200501677A2 (en) 2006-04-28

Family

ID=59280991

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200501677A EA200501677A2 (en) 2003-04-25 2004-04-26 PHOSPHONETIC CONTAINING CONNECTIONS (OPTIONS), PHARMACEUTICAL COMPOSITION (OPTIONS) AND DRUG FORM ON THEIR BASIS, METHOD OF TREATING CANCER (OPTIONS) AND METHOD OF PRESENTING THE CANCER OF OPERATORS

Country Status (1)

Country Link
EA (1) EA200501677A2 (en)

Similar Documents

Publication Publication Date Title
EA200501676A1 (en) PHOSPHONATE-CONTAINING KINASE INHIBITORS (OPTIONS), METHOD FOR THEIR RECEIVING, PHARMACEUTICAL COMPOSITION, PHARMACEUTICAL FORM ON THEIR BASIS AND METHOD FOR INHIBING KINASE IN MOLOPYTIC TREATMENT THEM
EA200700362A1 (en) CONJUGAT, CONTAINING ANTI-VIRUS COMPOUND, IN PARTICULAR INHIBITING HIV, PHARMACEUTICAL COMPOSITION AND SET OF STANDARD DOSE OF THE MEDICINAL DRUG ON ITS BASIS, METHOD OF INHIBITING THE SOFTWARE PRO.
CY1116373T1 (en) PHARMACEUTICAL PARTICLES CONTAINING METHYLNALTREXON
ATE472551T1 (en) TOCOPHEROL MODIFIED THERAPEUTIC DRUG COMPOUND
CY1112376T1 (en) 2,3,4,9-tetrahydro-1H-carvasol derivative as CRTH2 receptor antagonists
BRPI0406801A (en) Thieno-pyrimidinedione derivatives and their use in modulating autoimmune diseases
EA200602191A1 (en) 5.5-DESIGNED-2-AMINO-4-THIAZOLIDINONES AND METHOD FOR THEIR PRODUCTION, PHARMACEUTICAL COMPOSITION AND METHOD OF TREATMENT
MA27880A1 (en) TETRAHYDROCARBAZOLE DERIVATIVES AND THEIR PHARMACEUTICAL USE
EA200300776A1 (en) FENETHANOLAMINE DERIVATIVES FOR THE TREATMENT OF RESPIRATORY DISEASES
EA200700501A1 (en) COMPOSITION (OPTIONS) AND METHOD FOR THE TREATMENT OF HYPERPROLIFERATIVE PROCESSES, METHOD OF TREATING CANCER (OPTIONS) AND METHOD OF OBTAINING SOLID DISPERSION OF THE SUBSTANCE
IS2114B (en) Quinazoline derivatives to treat tumors
EA200401526A1 (en) NEW CONNECTIONS AND THEIR APPLICATION
EA200601212A1 (en) PHOSPHODESTERASE INHIBITORS, OBTAINING AND THEIR THERAPEUTIC APPLICATION
MA27093A1 (en) SULFONAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR APPLICATION AS MEDICAMENTS.
TW200510392A (en) Chemical compounds
IS6558A (en) Mixed disease treatment with vasoconstrictor
ES2328496T3 (en) 1,4,8-TRIAZA-ESPIRO (4,5) DECAN-2-ONA SUBSTITUTED COMPOUNDS.
EA200501868A1 (en) TRICYCLIC δ-OPIOID MODULATORS
SE0302139D0 (en) Novel compounds
TW200505452A (en) Chemical compounds
SE0402925D0 (en) Novel Compounds
EA200401250A1 (en) PHARMACEUTICAL COMPOSITIONS BASED ON MICROPARTICLES FOR INTRA-CANCER INTRODUCTION
EA200501821A1 (en) PHARMACEUTICAL COMBINATION, CONTAINING MODAFINIL AND OTHER DRUG PREPARATION
SE0300456D0 (en) Novel compounds
ATE353650T1 (en) COMBINATION THERAPY FOR THE TREATMENT OF CANCER